US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
TW432073B
(en)
*
|
1995-12-28 |
2001-05-01 |
Pfizer |
Pyrazolopyridine compounds
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
ATE418536T1
(de)
*
|
1996-08-12 |
2009-01-15 |
Celgene Corp |
Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
AU2001249755A1
(en)
*
|
2000-03-31 |
2001-10-15 |
Celgene Corporation |
Inhibition of cyclooxygenase-2 activity
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US7491634B2
(en)
*
|
2006-04-28 |
2009-02-17 |
Asm International N.V. |
Methods for forming roughened surfaces and applications thereof
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
AU2003222034A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Celgene Corporation |
(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
ZA200600682B
(en)
*
|
2002-03-20 |
2007-03-28 |
Celgene Corp |
(+)-2[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
|
US7498171B2
(en)
*
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
KR20050000400A
(ko)
*
|
2002-04-12 |
2005-01-03 |
셀진 코포레이션 |
줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도
|
EP1496878A4
(en)
*
|
2002-04-12 |
2007-12-26 |
Celgene Corp |
TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
NZ572388A
(en)
*
|
2002-05-17 |
2010-05-28 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
EP1556033A4
(en)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
WO2004004834A1
(en)
*
|
2002-07-02 |
2004-01-15 |
Qlt Inc. |
Compounds and methods for treating cancer and inflammation
|
BR0315316A
(pt)
*
|
2002-10-15 |
2005-08-16 |
Celgene Corp |
Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
AU2003285107B2
(en)
*
|
2002-10-31 |
2008-01-10 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
BR0316002A
(pt)
*
|
2002-11-06 |
2005-09-13 |
Celgene Corp |
Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
|
US7354948B2
(en)
|
2002-11-06 |
2008-04-08 |
Celgene Corporation |
Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
US20040167199A1
(en)
*
|
2002-11-18 |
2004-08-26 |
Celgene Corporation |
Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
WO2004045597A1
(en)
*
|
2002-11-18 |
2004-06-03 |
Celgene Corporation |
Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
US7173058B2
(en)
*
|
2002-12-30 |
2007-02-06 |
Celgene Corporation |
Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
|
DE602004010791T2
(de)
*
|
2003-03-03 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
|
US20040175382A1
(en)
*
|
2003-03-06 |
2004-09-09 |
Schafer Peter H. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
ZA200507322B
(en)
*
|
2003-03-06 |
2007-03-28 |
Celgene Corp |
Selective cytokine inhibitory drugs for treating disorders of the central nervous system
|
JP4713465B2
(ja)
*
|
2003-03-12 |
2011-06-29 |
セルジーン コーポレイション |
7−アミド−イソインドリル化合物およびその薬学的使用
|
CA2556706A1
(en)
*
|
2003-06-23 |
2005-01-06 |
Neurochem (International) Limited |
Treatment of amyloid- and epileptogenesis-associated diseases
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
CA2543132A1
(en)
*
|
2003-10-23 |
2005-05-19 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050142104A1
(en)
*
|
2003-11-06 |
2005-06-30 |
Zeldis Jerome B. |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
|
US20070208057A1
(en)
*
|
2003-11-06 |
2007-09-06 |
Zeldis Jerome B |
Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
|
CA2546493A1
(en)
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
US20050143420A1
(en)
*
|
2003-12-02 |
2005-06-30 |
Moutouh-De Parseval Laure |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
JP2007532641A
(ja)
*
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
CN1972684A
(zh)
*
|
2004-04-23 |
2007-05-30 |
细胞基因公司 |
用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
|
AU2004319814A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
US7244759B2
(en)
*
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
CN101309585A
(zh)
*
|
2004-10-28 |
2008-11-19 |
细胞基因公司 |
使用pde4调节剂治疗和控制中枢神经系统损伤的方法和组合物
|
JP2008523102A
(ja)
*
|
2004-12-13 |
2008-07-03 |
セルジーン・コーポレーション |
Pde4モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
TW200804347A
(en)
|
2006-01-10 |
2008-01-16 |
Janssen Pharmaceutica Nv |
Urotensin II receptor antagonists
|
CN101522197B
(zh)
|
2006-07-31 |
2013-12-11 |
詹森药业有限公司 |
尾加压素ⅱ受体拮抗剂
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
PA8782701A1
(es)
*
|
2007-06-07 |
2009-01-23 |
Janssen Pharmaceutica Nv |
Antagonistas del receptor de urotensina ii
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN102036663A
(zh)
*
|
2008-03-24 |
2011-04-27 |
细胞基因公司 |
用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎
|
WO2009120167A1
(en)
|
2008-03-27 |
2009-10-01 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
ES2379762T3
(es)
*
|
2008-08-02 |
2012-05-03 |
Janssen Pharmaceutica N.V. |
Antagonistas del receptor de la urotensina II
|
CA2736171A1
(en)
*
|
2008-09-10 |
2010-03-18 |
Celgene Corporation |
Processes for the preparation of aminosulfone compounds
|
BRPI1007500A2
(pt)
|
2009-02-10 |
2016-02-16 |
Celgene Corp |
métodos de uso e composições que compreendem moduladores de pde4 para tratamento, prevenção e gerenciamento de tuberculose
|
MX2011012122A
(es)
|
2009-05-14 |
2012-02-28 |
Tianjin Hemay Bio Tech Co Ltd |
Derivados de tiofeno.
|
ME01883B
(me)
|
2009-06-18 |
2014-12-20 |
Concert Pharmaceuticals Inc |
Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa
|
BR112012007737A2
(pt)
|
2009-10-09 |
2015-09-15 |
Celgene Corp |
processos para a preparação de compostos de 2-(1-feniletil)isoindolin-1-ona
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
MX341896B
(es)
|
2010-06-15 |
2016-09-07 |
Celgene Corp * |
Biomarcadores para el tratamiento de psoriasis.
|
WO2012083153A1
(en)
*
|
2010-12-16 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing apremilast moiety compounds
|
CN106008313B
(zh)
*
|
2010-12-22 |
2018-11-13 |
康塞特医药品有限公司 |
取代的异吲哚啉-1,3二酮衍生物
|
EP2663549B1
(en)
|
2011-01-10 |
2018-03-14 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
US9387195B2
(en)
|
2011-03-07 |
2016-07-12 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
MX367335B
(es)
|
2011-04-28 |
2019-08-15 |
Celgene Corp |
Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.
|
KR20210033073A
(ko)
*
|
2011-12-27 |
2021-03-25 |
암젠 (유럽) 게엠베하 |
(+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
|
AR090100A1
(es)
*
|
2012-02-21 |
2014-10-22 |
Celgene Corp |
Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
|
EP2730278A1
(en)
|
2012-11-08 |
2014-05-14 |
Ratiopharm GmbH |
Composition melt
|
AU2014235273A1
(en)
|
2013-03-14 |
2015-07-09 |
Celgene Corporation |
Treatment of psoriatic arthritis using apremilast
|
US9468605B2
(en)
|
2013-06-17 |
2016-10-18 |
Celgene Corporation |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
IN2014MU01283A
(el)
|
2014-04-04 |
2015-10-09 |
Cadila Healthcare Ltd |
|
US9994522B2
(en)
|
2014-05-11 |
2018-06-12 |
Mapi Pharma Ltd. |
Amorphous form of apremilast
|
WO2015175773A1
(en)
|
2014-05-15 |
2015-11-19 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
EP2949645A1
(en)
|
2014-05-28 |
2015-12-02 |
LEK Pharmaceuticals d.d. |
Processes for the preparation of ß-aminosulfone compounds
|
WO2015200177A1
(en)
|
2014-06-23 |
2015-12-30 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
EP3188745A1
(en)
|
2014-08-15 |
2017-07-12 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
CN105461610B
(zh)
*
|
2014-09-10 |
2018-04-13 |
杭州普晒医药科技有限公司 |
一种阿普斯特的晶型及其制备方法、药物组合物和用途
|
CN104761484B
(zh)
*
|
2014-11-24 |
2018-03-27 |
上海优拓医药科技有限公司 |
一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法
|
CN104496886A
(zh)
*
|
2014-12-11 |
2015-04-08 |
杭州新博思生物医药有限公司 |
一种高纯度阿普斯特b晶型的制备方法
|
CN107635962A
(zh)
|
2015-03-19 |
2018-01-26 |
印度商西伯拉有限公司 |
用于制备阿普斯特的改进工艺
|
WO2016161996A1
(en)
|
2015-04-09 |
2016-10-13 |
Zentiva, K.S. |
A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
|
WO2016169533A1
(en)
|
2015-04-24 |
2016-10-27 |
Zentiva, K.S. |
A solid form of apremilast and a process for preparing the same
|
US10370329B2
(en)
*
|
2015-04-27 |
2019-08-06 |
Mylan Laboratories Limited |
Process for the enantiomeric resolution of apremilast intermediates
|
CN104945306B
(zh)
*
|
2015-05-25 |
2017-07-21 |
山东铭康医药技术有限公司 |
制备光学纯阿普斯特的方法
|
CZ2015383A3
(cs)
|
2015-06-05 |
2016-12-14 |
Zentiva, K.S. |
Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
|
EP3106457A1
(en)
|
2015-06-15 |
2016-12-21 |
LEK Pharmaceuticals d.d. |
A novel synthetic pathway towards apremilast
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
EP3144393A1
(en)
|
2015-09-18 |
2017-03-22 |
LEK Pharmaceuticals d.d. |
A synthetic pathway towards apremilast
|
WO2017059040A1
(en)
|
2015-09-29 |
2017-04-06 |
Pliva Hrvatska D.O.O. |
Processes for the preparation of apremilast and intermediates thereof
|
US10682336B2
(en)
|
2015-10-21 |
2020-06-16 |
Amgen Inc. |
PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
|
WO2017085568A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Alembic Pharmaceuticals Limited |
An improved process and novel polymorphic form of apremilast
|
CN105294533A
(zh)
*
|
2015-12-02 |
2016-02-03 |
宋彤云 |
一种治疗骨病的药物组合物
|
WO2017179065A1
(en)
|
2016-04-15 |
2017-10-19 |
Davuluri Ramamohan Rao |
Improved process for the preparation of apremilast
|
WO2017216738A1
(en)
|
2016-06-15 |
2017-12-21 |
Torrent Pharmaceuticals Limited |
Topical compositions of apremilast
|
US10196355B2
(en)
|
2016-06-20 |
2019-02-05 |
Johnson Matthey Public Limited Company |
Forms of apremilast
|
CN106543050B
(zh)
*
|
2016-09-28 |
2018-04-10 |
中南大学湘雅医院 |
一种阿普斯特中间体的合成工艺
|
PL3590924T3
(pl)
*
|
2017-02-28 |
2022-01-24 |
Kangpu Biopharmaceuticals, Ltd. |
Nowa pochodna izoindoliny oraz jej kompozycja farmaceutyczna i zastosowanie
|
ES2866476T3
(es)
|
2017-04-04 |
2021-10-19 |
Quim Sintetica S A |
Compuestos de beta-aminosulfona racémicos
|
US11149003B2
(en)
*
|
2017-04-04 |
2021-10-19 |
Quimica Sintetica, S.A. |
Resolution of racemic beta-aminosulfone compounds
|
US10919855B2
(en)
|
2017-05-04 |
2021-02-16 |
Unichem Laboratories Ltd |
Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide
|
CN109422671B
(zh)
*
|
2017-08-31 |
2022-06-07 |
重庆医药工业研究院有限责任公司 |
一种阿普斯特中间体的制备方法
|
CA3075716A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
IL309150A
(en)
|
2017-10-23 |
2024-02-01 |
Boehringer Ingelheim Int |
A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
|
WO2019142124A1
(en)
|
2018-01-17 |
2019-07-25 |
Cadila Healthcare Limited |
Pharmaceutical compositions for treatment of vitiligo
|
BR112020021976A2
(pt)
|
2018-05-02 |
2021-01-26 |
Tianjin Hemay Pharmaceutical Co., Ltd. |
forma de cristal de derivado de tiofeno
|
CN110746376B
(zh)
*
|
2018-07-22 |
2024-04-30 |
上海星叶医药科技有限公司 |
苯并异硒唑酮胺类化合物及其制备方法和用途
|
CN110423213B
(zh)
*
|
2019-08-22 |
2021-06-04 |
上海英诺富成生物科技有限公司 |
一种阿普斯特衍生物及其制备方法与应用
|
EP3929179A1
(en)
|
2020-06-22 |
2021-12-29 |
Biohorm, S.L. |
Anti-inflammatory compounds and methods for their manufacture
|
CN113767104B
(zh)
*
|
2020-07-30 |
2023-08-22 |
百放英库医药科技(北京)有限公司 |
双功能化合物及其使用方法
|
CN114790164B
(zh)
|
2021-08-13 |
2022-12-27 |
苏州璞正医药有限公司 |
一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
|